This announcement is a separate document:
北京市康达律师事务所关于昭衍新药注销2018年、2019年、2020年股权激励计划部分股票期权的法律意见书
Legal Opinion of Beijing Kangda Law Firm on Zhaoyan New Pharmaceutical\'s Cancellation of Some Stock Options in the 2018, 2019, and 2020 Equity Incentive Plans
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.